The effect of sacubiltril/valsartan in the treatment of elderly heart failure and its effect on serological indexes
-
摘要: 目的:探讨沙库巴曲缬沙坦对比传统血管紧张素转化酶抑制剂(ACEI)和血管紧张素Ⅱ受体拮抗剂(ARB)类药物对老年心力衰竭患者的临床疗效及其对血清中可溶性ST2(sST2)、血管紧张素Ⅱ(AngⅡ)、N末端脑钠肽前体(NT-proBNP)、血清肌酐(SCr)及肾小球滤过率(eGFR)的影响。方法:选取2018-04-2019-01于蚌埠医学院第一附属医院心内科就诊的老年心力衰竭患者,随机分为两组,其中观察组为接受沙库巴曲缬沙坦治疗者52例,对照组为接受传统ACEI/ARB药物治疗者60例,分别对两组患者进行约6个月的随访,对比两组患者治疗前后左室射血分数(LVEF)、左室舒张末期内径(LVEDD)、左室收缩末期内经(LVESD),血清指标NT-proBNP、sST2、AngⅡ,以及肾脏功能指标SCr、eGFR。结果:与治疗前相比较,两组患者治疗后LVEF、LVEDD、LVESD、NT-proBNP、sST2及AngⅡ均有所改善,且观察组改善程度明显优于对照组(均P<0.05);两组患者治疗后肾脏功能指标SCr与eGFR均较治疗前改善(均P<0.05),且观察组SCr较对照组改善更为明显(P<0.05)。结论:沙库巴曲缬沙坦治疗老年心力衰竭临床疗效较传统药物有明显优势,可明显改善患者心脏功能,抑制心肌重构,且能更好地改善血清学指标。Abstract: Objective:To compare the clinical efficacy of sacubiltrril/valsartan with traditional ACEI and ARB drugs in elderly patients with heart failure and to investigate its effects on soluble ST2,AngⅡ,NT-proBNP,SCr and eGFR in serum.Method:The elderly patients with heart failure in the Department of Cardiology,the First Affiliated Hospital of Bengbu Medical College from April 2018 to January 2019 were randomly divided into two groups.Fifty-two patients treated with sakubatra/valsartan were included into observation group,and 60 patients treated with traditional ACEI/ARB drugs were included into control group.All patients were followed up for about 6 months.Left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic menstruation(LVESD),NT-proBNP,sST2,AngⅡ,SCr,and eGFR before and after treatment were compared between control group and observation group.Result:Compared with before treatment,LVEF,LVEDD,LVESD,NT-proBNP,sST2 and AngⅡ in the two groups were improved after treatment,and the improvement degree in the observation group was significantly better than that in the control group(all P<0.05).The renal function indexes SCr and eGFR in the two groups were improved after treatment(all P<0.05),and SCr in the observation group was improved more obvious than that in the control group(P<0.05).Conclusion:Sakubatril/valsartan has obvious advantages over traditional drugs in the treatment of elderly heart failure.It can improve cardiac function,inhibit myocardial remodeling, and improve serological indexes.
-
Key words:
- heart failure /
- sacubiltrril/valsartan /
- sST2
-
-
[1] 中华医学会心血管病学分会心力衰竭组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病学杂志,2018,10(46):760-789.
[2] Su A,Al'Aref SJ,Beecy AN,et al.Clinical and socioeconomic predictors of heart failure readmissions:A review of contemporary literature[J].2019,94(7):1304-1320.
[3] Engeli S,Stinkens R,Heise T,et al.Effect of Sacubiltril/Valsartan on exercise-induced lipid metabolism in patients with obesity and hypertension[J].Hypertension,2018,71(1):70-77.
[4] 张薇琳,周海英,杨小明.双效血管紧张素受体-脑啡肽酶抑制剂沙库巴曲/缬沙坦的研究进[J].世界临床药物,2017,38(12):851-854.
[5] Mueller C,McDonald K,de Boer RA,et al.Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations[J].2019,21(6):715-731.
[6] Coronado MJ,Bruno KA,Biluwet LA,et al.Elevated sera sST2is associated with heart failure in men≤50years old with myocarditis[J].2019,8(2):e008968.
[7] Huang A,Qi X,Hou W,et al.Prognostic value of sST2and NT-proBNP at admission in heart failure with preserved,midranged and reduced ejection fraction[J].Acta Cardiol,2018,73(1):41-48.
[8] Jirak P,Fejzic D,Paar V,et al.Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2,GDF-15,suPAR and H-FABP in patients with chronic heart failure[J].Acta Pharmacol Sin,2018,39(7):1189-1196.
[9] 吕海珍,吕云,周荣,等.血清SCY、sST2和NT-proB-NP联合检测对慢性心力衰竭诊断及心功能评价的价值[J].中国实验诊断学,2019,6(23):102-106.
[10] Liu X,Shan X,Chen H,et al.Stachydrine ameliorates cardiac fibrosis through inhibition of angiotensinⅡ/transformation growth factorβ1fibrogenic axis[J].Front Pharmacol,2019,10:538.
-
计量
- 文章访问数: 286
- PDF下载数: 142
- 施引文献: 0
下载: